Effect of tetrandrine combined with Droloxifen on the expression of bcr/abl of K562 at both mRNA and protein levels.
- Author:
Bao-An CHEN
1
;
Xi-Jun QIAN
;
Jian CHENG
;
Feng GAO
Author Information
1. Department of Hematology, Zhongda Hospital, Sourtheast University, Nanjing 210009, China. bachen@seu.edu.cn
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
pharmacology;
Benzylisoquinolines;
pharmacology;
Blotting, Western;
Down-Regulation;
drug effects;
Drug Synergism;
Fusion Proteins, bcr-abl;
biosynthesis;
genetics;
Gene Expression Regulation, Leukemic;
drug effects;
Humans;
K562 Cells;
RNA, Messenger;
biosynthesis;
genetics;
Reverse Transcriptase Polymerase Chain Reaction;
Tamoxifen;
analogs & derivatives;
pharmacology
- From:
Journal of Experimental Hematology
2005;13(1):95-99
- CountryChina
- Language:Chinese
-
Abstract:
To observe the effect of Tetrandrine (tet) combined with Droloxifen (DRL) on the expression of bcr/abl mRNA and P(210) BCR/ABL protein of K562 cell line, after K562 cells were cultured in the medium containing Tet (1 micromol/L), DRL (5 micromol/L) separately or in their combination for some time, the changes of bcr/abl mRNA and protein expression were detected by RT-PCR and Western blot respectively. The results showed that the application of single drug of Tet or DRL had no effect on bcr/abl mRNA and BCR/ABL protein expression in K562 cell line. However, Tet in combination with DRL began to downregulate bcr/abl mRNA and P(210) BCR/ABL expression of K562 cells at 48 h and 72 h, respectively. It is concluded that tetrandrine in combination with Droloxifen can downregulate the expression of bcr/abl mRNA and P(210) BCR/ABL protein and the combination may be involved in the mechanism underlying the reverse effects on multidrug resistance in leukemia.
